Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

February 9, 2021 updated by: Lecube, Albert, M.D.

Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)

Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and the GLP-1 receptor has been found in significant amounts in the lung, it could be hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced pulmonary function

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

There is growing evidence to suggest an association between type 2 diabetes and impaired pulmonary function. In this regard, several cross-sectional studies have appeared showing decreased indices of forced expiration, lung volume and diffusion capacity as the main lung dysfunctions detected in type 2 diabetic populations. In fact, diabetes is frequently co-morbid with chronic obstructive pulmonary disease, and data from the Atherosclerosis Risk in Communities Study showed a faster pulmonary function decline in type 2 diabetic patients than in other participants. This is important because the reduction of FEV1 has been demonstrated an independent cause of mortality in diabetic patients.

Interestingly, lung function measures start to decrease several years before the diagnosis of diabetes. In this regard an investigation found that insulin resistance is an independent determinant of pulmonary function in non-diabetic morbidly obese women. In addition, the results suggest that the metabolic pathways related to insulin resistance are crucial in initiating lung abnormalities in type 2 diabetic patients.

The reasons for the association between respiratory disease and diabetes are unclear. However, the relationship between type 2 diabetes and muscle strength, the impairment in lung elastic properties, and the presence of a low-grade chronic inflammation state are involved. In supporting these findings, thickening of the alveolar epithelia and pulmonary capillary basal lamina, fibrosis, centrilobular emphysema, and pulmonary microangiopathy have been detected in autopsies of diabetic patients. In addition, defects in the bronchiolar surfactant layer, which is involved in maintaining airway stability and diameter, may also be considered a contributing factor to the impairment of airway calibre regulation in diabetic patients. When the alveolocapillary barrier is damaged, surfactant proteins leak into the bloodstream. A recent population-based random sample study has described how increased circulating levels of surfactant protein A, the major surfactant-associated protein, were associated with altered glucose tolerance and insulin resistance. Therefore, surfactant defects in diabetic individuals may also lead to an increase in airway resistance and to a reduction in ventilatory patterns as observed in our studies. In addition, as experimental studies have shown that glucagon-like peptide 1 plays a role in the stimulation of surfactant production, its underlying deficit in type 2 diabetes could also enhance the airway resistance observed in these patients. However, the beneficial effects on pulmonary function using incretin-based therapies remain to be elucidated.

Clinical trial study hypothesis is that treatment with an incretin mimetic such as liraglutide may ameliorate lung function parameters in type 2 diabetics patients, independently of weight reduction. This hypothesis is based on the following factors:

  1. - There is growing evidence to suggest an association between type 2 diabetes and impaired pulmonary function.
  2. - In patients with type 2 diabetes, the incretin effect is severely reduced or absent, contributing to the reduced lung function parameters observed in type 2 diabetic patients.
  3. - GLP-1 stimulates surfactant production in "in vitro" studies and, in consequence, the increase in surfactant production induced by liraglutide could be the main factor involved in the respiratory improvement.

Study Type

Interventional

Enrollment (Actual)

76

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Barcelona, Spain, 08035
        • Hospital Universitari Vall d´Hebrón
      • Lleida, Spain, 25198
        • Hospital Universitari Arnau de Vilanova de Lleida
      • Málaga, Spain, 29010
        • Hospital Universitario Virgen de la Victoria
      • Sevilla, Spain, 41013
        • Hospital Universitario Virgen del Rocio
    • Barcelona
      • Badalona, Barcelona, Spain, 08916
        • Hospital Universitari Germans Trias i Pujol
    • Navarra
      • Pamplona, Navarra, Spain, 31008
        • Clinica Universidad de Navarra

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Signed informed consent.
  • Subjects between 40 and 65 years old. Diagnosis of type 2 diabetes mellitus with more than 5 years of evolution of disease.
  • Metformin (alone or in combination with sulfonylurea and / or insulin and / or thiazolidinediones) at a stable dose for at least the past 3 months.
  • HbA1c ≥ 7,0 y ≤ 9,0 %.
  • BMI between 30 and 40 kg / m2.
  • No pulmonary disease (COPD, asthma, fibrosis, etc) known.
  • Baseline FEV1 decline of equal or greater than 10% in the percentage of the theoretical value.
  • Chest radiography without significant changes in the lung parenchyma

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Treatment with inhibitors of dipeptidyl peptidase 4 glitazones and / or
  • SGLT2 inhibitors.
  • Active and former smokers for less than five years ago smoking.
  • Chronic obstructive pulmonary disease.
  • Respiratory sleep disorders that require treatment with continuous positive pressure in the airway.
  • Asthma treatment with bronchodilators.
  • Previous bariatric surgery.
  • Cardiovascular disease, heart failure and / or stroke.
  • Pathology of the chest wall.
  • Serum creatinine> 1.7 mg / dl.
  • Abnormal results in liver function test (Alanine transaminase/ Aspartate Aminotransferase greater than twice the upper limit of normal).
  • History of acute or chronic pancreatitis.
  • Personal or family history of medullary thyroid cancer or Multiple
  • Endocrine Neoplasia (MEN ) type 2.
  • Active neoplasms or neoplastic patients considered disease-free history from less than 5 years ago.
  • Women of childbearing age who are pregnant (positive pregnancy test within 14 days before the start of treatment) or intend to get pregnant.
  • Lactating women.
  • Women of childbearing potential not using adequate contraception (such as oral contraceptives, intrauterine device or barrier method of birth control along with spermicide or surgical sterilization) or unwilling to use during the study (as required by local laws or practices).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: liraglutide
7-week subcutaneous liraglutide treatment once daily
Drug: liraglutide
7-week subcutaneous liraglutide once daily
OTHER: placebo
7-week subcutaneous placebo treatment once daily.
Drug: placebo
7-week subcutaneous placebo once daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)
Time Frame: 7 weeks

Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second (FEV1).

Mean difference between 7 weeks after treatment visit and baseline visit is registered.
7 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes From Baseline on Measurements of Respiratory Function Defined by Forced Vital Capacity (FVC)
Time Frame: 7 weeks

Changes from baseline on measurements of respiratory function defined by forced vital capacity (FVC).

Mean difference between 7 weeks after treatment visit and baseline visit is registered.
7 weeks
Changes From Baseline in Serum Levels of Surfactant A and D Protein
Time Frame: 7 weeks
Changes from baseline in serum levels of surfactant A and D protein. Values for surfactant A or D protein after 7 treatment weeks (liraglutide or placebo) are registered.
7 weeks
Changes From Baseline on Measurements of Respiratory Function Defined by Maximum Mid-expiratory Flow (FEF25-75)
Time Frame: 7 weeks

Changes from baseline on measurements of respiratory function defined by Maximum mid-expiratory flow (FEF25-75).

Mean difference between 7 weeks after treatment visit and baseline visit is registered.
7 weeks
Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second/Forced Vital Capacity (FEV1/FVC)
Time Frame: 7 weeks

Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC).

Mean difference between 7 weeks after treatment visit and baseline visit is registered.
7 weeks
Changes From Baseline on Measurements of Respiratory Function Defined by Residual Volume (RV)
Time Frame: 7 weeks
Changes from baseline on measurements of respiratory function defined by residual volume (RV).
7 weeks
Changes From Baseline on Measurements of Respiratory Function Defined by Total Lung Capacity (TLC)
Time Frame: 7 weeks
Changes from baseline on measurements of respiratory function defined by Total lung capacity (TLC).
7 weeks
Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC)
Time Frame: 7 weeks

Changes from baseline on measurements of respiratory function defined by Residual functional capacity (RFC) are registered.

However, this parameter was not determined in patients due to an error in the programm used.
7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lecube, Albert, M.D.

Collaborators

Novo Nordisk A/S
Dynamic Solutions

Investigators

  • Study Director: Albert Lecube, PhD, Hospital Universitari Arnau de Vilanova de Lleida

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 4, 2016

Primary Completion (ACTUAL)

November 18, 2019

Study Completion (ACTUAL)

December 16, 2019

Study Registration Dates

First Submitted

August 25, 2016

First Submitted That Met QC Criteria

September 2, 2016

First Posted (ESTIMATE)

September 5, 2016

Study Record Updates

Last Update Posted (ACTUAL)

February 26, 2021

Last Update Submitted That Met QC Criteria

February 9, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LIRALUNG

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes

Clinical Trials on liraglutide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe